October 17, 2023 11:37 AM EDT
R&D

Apel­lis’ C3 in­hibitor shows bio­mark­er im­pact in small PhII rare kid­ney dis­ease tri­al

Ayisha Sharma

News Reporter

Apel­lis Phar­ma­ceu­ti­cal’s pegc­eta­coplan has shown hints of ef­fi­ca­cy in a hand­ful of pa­tients with rare kid­ney dis­eases in a Phase II tri­al, five months af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times